Hope Medicine received US FDA clearance to begin a Phase 2 trial (180 participants, HMI-115 vs placebo over 24 weeks) after positive Phase 1b results.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Phase 2
How it works
Monoclonal antibody against the prolactin receptor (PRLR); blocking PRLR signalling is hypothesized to relieve prolactin-driven suppression of hair follicles.
Results so far
Phase 1b: average non-vellus target area hair count increased by 14 hairs/cm2 from baseline in two male patients; drug reported safe and well tolerated. Note the very small n reported in the search summary.
What's next
Phase 2 enrollment underway as of research date; no Phase 3/filing timeline publicly stated.
In India
No India-specific development identified.
Sources
- News report ↗ (accessed 2026-10-17)
- Company announcement ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.